Treatment with the potent but promiscuous TXNRD1 inhibitor, auranofin, in a hemochromatosis mouse model showed an increase in hepatic malondialdehyde (MDA), a product of lipid peroxidation, and Ptgs2 mRNA levels, which is highly associated with ferroptosis [37]. The gene discussed is TXNRD1; the disease is hemochromatosis type 1.